Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680803 | 1.00 | ADRB3 (0.47) | ADRB3LPAR1LPAR5TP53ADRB1 | |
| SCHEMBL6681935 | 0.96 | ADRB3 (0.43) | ADRB3LPAR1LPAR5TP53ADRB1 | |
| SCHEMBL6805643 | 0.96 | ADRB3 (0.43) | ADRB3LPAR1LPAR5TP53ADRB1 | |
| SCHEMBL6801224 | 0.93 | ADRB3 (0.43) | ADRB3LPAR1LPAR5TP53ADRB1 | |
| SCHEMBL6677084 | 0.92 | TP53 (0.45) | ADRB3TP53ADRB1CYP4F2CYP4A11 | |
| SCHEMBL6804359 | 0.92 | TP53 (0.45) | ADRB3TP53ADRB1CYP4F2CYP4A11 | |
| SCHEMBL6541193 | 0.91 | TP53 (0.51) | ADRB3TP53ADRB1MAPT | |
| SCHEMBL6541200 | 0.91 | TP53 (0.51) | ADRB3TP53ADRB1MAPT | |
| SCHEMBL6802131 | 0.91 | LPAR1 (0.46) | ADRB3LPAR1LPAR5TP53ADRB1 | |
| SCHEMBL6677034 | 0.90 | ADRB3 (0.44) | ADRB3TP53ADRB1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | ADRB3 150/4885LPAR1 1110/4885LPAR5 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.